All Stories

AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly statistically significant” efficacy in a key trial.

Apr 21, 2025 - 15:42
 0
AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer
AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly statistically significant” efficacy in a key trial.
Read More

Tags:

Previous Article

Amneal recalls 2 lots of hospital anesthetic over plastic contamination fears

Next Article

Police Department Saves Thousands Of Dollars Each Month Using Electric Vehicles

Related Posts

An additional treatment option with TAGRISSO® (osimertinib)

An additional treatment option with TAGRISSO® (osimerti...

Feb 10, 2025  0

Bridging the gap from clinical trials to real life HIV care

Bridging the gap from clinical trials to real life HIV ...

Mar 10, 2025  0

Viking pays $150M to recruit CordenPharma for obesity drug manufacturing saga

Viking pays $150M to recruit CordenPharma for obesity d...

Mar 11, 2025  0